Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S. Tessoulin B, et al. Among authors: bossard c. Ann Hematol. 2017 Jun;96(6):943-950. doi: 10.1007/s00277-017-2981-2. Epub 2017 Apr 3. Ann Hematol. 2017. PMID: 28374163
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Sortais C, Lok A, Tessoulin B, Gastinne T, Mahé B, Dubruille V, Blin N, Touzeau C, Moreau A, Bossard C, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Chevallier P, Moreau P, Leux C, Le Gouill S. Sortais C, et al. Among authors: bossard c. Ann Hematol. 2020 Jul;99(7):1595-1604. doi: 10.1007/s00277-020-04025-2. Epub 2020 May 16. Ann Hematol. 2020. PMID: 32417940
Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.
Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubruille V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S. Loirat M, et al. Among authors: bossard c. Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12. Ann Oncol. 2015. PMID: 25392158 Free article.
Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Voldoire M, Guillaume T, Peterlin P, Gallas P, Garnier A, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Chevallier P, Moreau P, Le Gouill S. Bourcier J, et al. Among authors: bossard c. Ann Hematol. 2016 Aug;95(8):1287-93. doi: 10.1007/s00277-016-2705-z. Epub 2016 Jun 14. Ann Hematol. 2016. PMID: 27297970
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, Bodet-Milin C, Ragot S, Bossard C, Nadal N, Herbaux C, Tessoulin B, Tchernonog E, Rossi C, McCulloch R, Gastinne T, Callanan MB, Rule S. Le Gouill S, et al. Among authors: bossard c. Blood. 2021 Feb 18;137(7):877-887. doi: 10.1182/blood.2020008727. Blood. 2021. PMID: 33181832 Free article. Clinical Trial.
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.
Le Calvez B, Le Bris Y, Herbreteau G, Jamet B, Bossard C, Tessoulin B, Gastinne T, Mahé B, Dubruille V, Blin N, Antier C, Theisen O, Kraeber-Bodéré F, Le Gouill S, Béné MC, Moreau P, Touzeau C. Le Calvez B, et al. Among authors: bossard c. EJHaem. 2020 Aug 6;1(1):318-322. doi: 10.1002/jha2.8. eCollection 2020 Jul. EJHaem. 2020. PMID: 35847743 Free PMC article.
Hot lungs, bitter cherry: intravascular lymphoma.
Génin V, Enfrein A, Lecouffe-Desprets M, Gallas P, Bossard C, Moreau A, Ansquer C, Hamidou M, Agard C, Néel A. Génin V, et al. Among authors: bossard c. QJM. 2018 Jan 1;111(1):53-54. doi: 10.1093/qjmed/hcx224. QJM. 2018. PMID: 29186525 No abstract available.
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B-cell lymphoma, a lymphoma study association (LYSA) retrospective study.
Bonnet A, Bossard C, Gabellier L, Rohmer J, Laghmari O, Parrens M, Sarkozy C, Dulery R, Roland V, Llamas-Gutierrez F, Oberic L, Fornecker LM, Bounaix L, Villemagne B, Szablewski V, Choquet S, Bouabdallah K, Traverse-Glehen A, Mohty M, Sanhes L, Houot R, Gastinne T, Leux C, Le Gouill S. Bonnet A, et al. Among authors: bossard c. Cancer Med. 2022 Oct;11(19):3602-3611. doi: 10.1002/cam4.4742. Epub 2022 May 10. Cancer Med. 2022. PMID: 35538643 Free PMC article.
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C. Vercellino L, et al. Among authors: bossard c. Blood Adv. 2020 Nov 24;4(22):5607-5615. doi: 10.1182/bloodadvances.2020003001. Blood Adv. 2020. PMID: 33180899 Free PMC article.
147 results